Psilocybin and Spirituality: Science at the Edge of the Sacred

Psilocybin and the Mystical Experience

96% of clergy rated psilocybin among their top-5 spiritual experiences at 16 months

In a 2025 randomized controlled trial of 21 clergy from major world religions, 96% still rated their psilocybin sessions among the most spiritually significant experiences of their lifetime at 16-month follow-up.

Griffiths et al., Psychedelic Medicine, 2025

67%

of hallucinogen-naïve adults had a complete mystical experience during high-dose psilocybin in the foundational 2006 Hopkins trial (Griffiths 2006)

14 months

after the 2006 study, 58% of participants still rated their psilocybin experience among the top-5 most personally meaningful events of their lives (Griffiths 2008)

NDE-equivalent

psilocybin experiences produce changes in death attitudes comparable to near-death experiences — both reduce death fear at similar magnitudes (Sweeney 2022)

Griffiths et al., Psychedelic Medicine, 2025

View as image ↗

Ninety-six percent of professional religious leaders — clergy from Christianity, Judaism, Islam, Buddhism, and other major world traditions — rated their psilocybin experience among the most spiritually significant events of their lives, still holding that assessment 16 months later. This finding, from a 2025 randomized controlled trial by Griffiths and colleagues, is not from spiritual seekers or retreat-goers who might be predisposed to interpret intense experiences through a sacred lens.^[1] It is from people whose entire professional and intellectual lives are organized around evaluating spiritual experience — trained theologians, ordained ministers, rabbis, imams, and Buddhist monastics. They had frameworks. They had comparators. They had decades of prior spiritual practice. And still, the psilocybin sessions landed in their top five.

The science of psilocybin spirituality is not new. It began seriously in 2006 with the first modern randomized controlled trial of psilocybin in healthy volunteers. What has accumulated since is a body of evidence for a phenomenon that is simultaneously measurable, replicable, and genuinely resistant to simple explanation.

For the broader pharmacology of what psilocybin does in the brain, see How Psilocybin Works: The Complete Pharmacology Guide.

The 2025 Clergy Study: When Professional Religious Leaders Call It Sacred

Most psilocybin spirituality research has enrolled healthy volunteers — people drawn to participate partly through curiosity about intense experiences. The Griffiths 2025 clergy trial was different in design.^[1]

Twenty-one clergy were enrolled: ordained ministers, priests, rabbis, imams, and Buddhist monastics from multiple major religious traditions. They were assigned in a parallel group design — some received psilocybin sessions, others were placed on a waitlist — making this a proper randomized controlled trial rather than a pre-post study. The research question was pointed: does psilocybin alter how professional religious leaders experience their vocation, their practices, and their relationship to other traditions?

At 16-month follow-up, 96% of psilocybin participants rated their sessions among the five most spiritually significant experiences of their lifetime. The sessions also produced measurable changes: increased engagement in contemplative practices (prayer, meditation, ritual), improved attitudes toward their spiritual vocation, and greater appreciation of religious traditions outside their own.

This last finding — increased appreciation of other traditions — is particularly interesting. The participants were not softening their beliefs. They were expanding their capacity to recognize value in different frameworks. Clergy who had spent decades in specific theological traditions emerged from psilocybin sessions with, as the researchers documented, a broader sense of spiritual common ground.

The significance of this study is what the participants bring to the table. They are not naive about spiritual experience. A Buddhist monastic who has spent 20 years in meditation practice and rated the psilocybin session among their top-5 lifetime spiritual events is making a comparison against substantial prior experience. A rabbi with decades of prayer, study, and pastoral care is doing the same. These are not people who had their first deep inner experience on psilocybin and rated it highly by default. They had context. They had vocabulary. They still rated it as extraordinary.

Where the Science Started: From 1962 to the Hopkins Laboratory

This research has a pre-history. In 1962, a Harvard divinity student named Walter Pahnke administered psilocybin to seminary students in a chapel during a Good Friday service and documented striking experiences of mystical unity and spiritual significance. The methodology was criticized heavily — blinding was imperfect, Pahnke was personally invested in the outcome — and the study could not meet modern standards. But the central question it raised never went away: could a compound reliably occasion genuine spiritual experience?

The answer came formally in 2006, when Roland Griffiths and colleagues at Johns Hopkins published the first modern, rigorously controlled trial of psilocybin in healthy adults.^[2]

Thirty-six hallucinogen-naïve volunteers received either high-dose psilocybin (30 mg per 70 kg of body weight) or methylphenidate (a stimulant used as an active comparator) in a double-blind crossover design. The methodological innovations were deliberate and substantial: participants were pre-screened to ensure they had no personal or family history of psychiatric conditions. Support staff were trained. The physical setting was designed to be comfortable and aesthetically neutral. Participants were prepared for the experience in advance and debriefed afterward. Every element that had made earlier research dismissible was addressed.

In 67% of participants, psilocybin occasioned what researchers classified as a complete mystical experience — defined using a validated questionnaire measuring unity, transcendence, sacredness, and ineffability. At 2-month follow-up, participants rated the session as one of the five most personally meaningful and spiritually significant experiences of their lives.

For a detailed account of the 2006 study's design and what made it the inflection point in modern psychedelic research, see The Griffiths 2006 Study: The Experiment That Changed Everything.

What Stays 14 Months Later: Meaning, Personality, and Lasting Change

The 2006 findings could have been a fleeting afterglow — post-experience enthusiasm that fades as ordinary life resumes. The 14-month follow-up data suggested otherwise.

Griffiths and colleagues published the 14-month follow-up of the same 2006 cohort in 2008.^[3] At 14 months, 58% of participants still rated their psilocybin experience among the five most personally meaningful events of their lives. Sixty-seven percent still rated it among the five most spiritually significant. Sixty-four percent reported increased well-being or life satisfaction that they attributed, at least in part, to the psilocybin session.

The follow-up also collected reports from community observers — friends, family members, colleagues who knew the participants and were asked to assess whether they had changed. The observers corroborated the self-reports. The people around these participants noticed the changes.

MacLean, Johnson, and Griffiths went further in a 2011 analysis of a related cohort.^[4] Using validated Big Five personality assessments administered before and after psilocybin sessions, they found something that personality psychology had considered essentially impossible: significant lasting increases in Openness — the trait associated with curiosity, aesthetic sensitivity, intellectual engagement, and imagination — in participants who had complete mystical experiences.

Personality traits in adults over 25 are considered stable. Decades of research have found that they change slowly if at all, and major environmental events have surprisingly small effects on them. Finding a significant increase in Openness that persisted to 14-month follow-up was, as MacLean and colleagues put it, unprecedented.

The effect was specific to mystical experience. Participants who received psilocybin but did not have a complete mystical experience did not show the same Openness increase. The molecule was not doing the work independently. The nature of the experience mattered.

For more on how the experience quality predicts outcomes, see How the Mystical Experience Predicts Therapeutic Outcomes.

Psilocybin and Near-Death Experiences: Surprisingly Similar Data

One of the most conceptually interesting comparisons in the psilocybin literature involves an experience that has nothing to do with drugs: the near-death experience (NDE).

People who have had near-death experiences — cardiac arrest survivors who report tunnels, light, encounters with deceased relatives — consistently report lasting changes in how they feel about death. Fear of death decreases. The sense that life has meaning increases. The boundary between self and something larger softens.

Sweeney and colleagues, working from Griffiths' research group, published a survey in 2022 comparing psilocybin-occasioned experiences directly with near-death and other non-ordinary experiences in terms of their effect on death attitudes.^[5] Approximately 90% of people who had psychedelic experiences reported being less afraid of death afterward. The magnitude of change in death attitudes across psilocybin experiences and NDEs was comparably significant — not identical, but in the same range.

This comparison raises a question that science can frame but not fully resolve. NDEs happen to people who are clinically close to death — the experience arises in a context of genuine proximity to dying. Psilocybin experiences happen to people who are not dying. But the two experiences produce comparable shifts in how people relate to mortality. Either both are tapping something real about the nature of death and what lies beyond it, or both are producing the same neurological states that the human brain associates with transcending ordinary selfhood — states that human minds historically interpret as sacred.

The research cannot adjudicate between these interpretations. What it can confirm is that the experiential output is remarkably similar, and the outcome — reduced death fear, increased meaning — is real and measurable regardless of the trigger.

For more on this NDE-psilocybin parallel and its implications for end-of-life care, see How Psilocybin Changes the Relationship with Mortality.

How Long Does the Spiritual Effect Last?

Psilocybin's spiritual significance to participants is not a temporary glow that fades. The long-term evidence is consistent.

Agin-Liebes and colleagues tracked 16 surviving participants from the Ross 2016 NYU cancer trial at a mean of 4.5 years after their psilocybin sessions.^[6] Seventy-one percent rated the psilocybin session among the five most personally meaningful experiences of their entire lives. This is particularly striking because these were cancer patients — people whose lives contained extreme events, including terminal diagnoses, loss, and confrontations with mortality that most people never face. Against that backdrop, 71% still rated a single drug session as among the most personally meaningful events of their lives.

The clergy study reported 96% at 16 months. The healthy volunteer follow-up reported 58-67% at 14 months. The cancer patient cohort reported 71% at 4.5 years. Across different populations, different research teams, different time horizons — the pattern is consistent. The experience lodges.

It lodges, the researchers argue, because it is not simply a vivid memory. It is an experience that changes how people understand themselves and their relationship to the world. The Openness finding from MacLean 2011 captures this — the experience does not just create a lasting memory; it appears to reshape the perceptual and interpretive dispositions through which subsequent experience is processed.

For more on how psilocybin alters brain connectivity as the neural substrate for these lasting changes, see What Happens in Your Brain on Psilocybin? A Neuroscience Explainer.

The Hard Question: Does Psilocybin Create Genuine Spiritual Experience?

Science has documented that psilocybin reliably occasions states that participants classify as spiritual, that professional religious leaders consider among the most significant experiences of their theological lives, and that produce lasting changes in how people relate to mortality, meaning, and each other. What science cannot settle is the question that most people reading this article are probably actually asking: is it real?

The question splits along philosophical lines that go back centuries. One position: the experience is real in the sense that matters — it changes people, it produces insights that persist, it alters the relationship to self and world in ways that are measurable and beneficial. Whether or not a molecule occasioned it, the transformation is genuine. Sacredness is not diminished by having a cause.

The other position: if a molecule can produce the phenomenology of spiritual experience on demand — the unity, the transcendence, the overwhelming significance — without the conditions that traditionally give rise to such states (prayer, practice, community, suffering), then what psilocybin produces is a convincing simulation of the real thing. It produces the feeling of spirituality without the earned context that gives it meaning.

Neither position is obviously correct. The clergy study does not resolve this. If anything, it deepens the puzzle: people who have earned their spiritual context through years of practice still rated the psilocybin session as extraordinary. That fact is harder to dismiss as mere simulation.

The research literature does not take sides in this debate. It reports what participants say, what it measures them doing, and how long the changes last. Whether the experience is sacred in the theological sense is not a question a measurement instrument can answer. What the instruments consistently show is that something significant happens — and that the people who experience it treat it as among the most important things that have ever happened to them.

For the measurable dimensions of these states and how they're quantified, see Oceanic Boundlessness and Ego Dissolution: Quantifying the Mystical Experience. For the broader picture of what psilocybin does and what spiritual experience has to do with therapeutic outcomes, see Psilocybin and the Mystical Experience: What Research Shows.

The Bottom Line

The science of psilocybin and spirituality is unusually consistent across populations and time horizons. From hallucinogen-naïve volunteers in 2006 to professional clergy in 2025, participants rate single psilocybin sessions among the most spiritually significant events of their lives, and they maintain that assessment years later. The near-death comparison adds depth: psilocybin-occasioned experiences produce the same shift in death attitudes as clinical proximity to dying. What the research cannot resolve is whether the experience is spiritually genuine in any theological sense. What it has repeatedly confirmed is that something meaningful happens, and it persists.

Frequently Asked Questions

Is psilocybin used in religious ceremonies?

Psilocybin-containing mushrooms have been used in indigenous ceremonial contexts for centuries, particularly in Mesoamerican traditions. In modern research, psilocybin is not used in ongoing religious ceremonies, but a 2025 randomized controlled trial specifically enrolled active clergy from major world religions (Christianity, Judaism, Islam, Buddhism, and others) and found the sessions enhanced their contemplative practices and spiritual vocation engagement. The intersection of psilocybin with established religious traditions is an active area of clinical research.

Can psilocybin increase spiritual beliefs?

Research suggests psilocybin can increase certain aspects of spiritual orientation, particularly those related to a sense of connection, meaning, and reduced fear of death. MacLean and colleagues (2011) found lasting increases in the personality trait of Openness — associated with aesthetic sensitivity and intellectual engagement — following complete mystical experiences. The 2025 clergy study found increased appreciation of other religious traditions. The changes appear to deepen existing frameworks rather than replace them.

What do religious leaders think of psilocybin?

In the only controlled study of this question — Griffiths and colleagues' 2025 randomized trial of 21 clergy from major world religions — 96% rated their psilocybin sessions among the top-5 most spiritually significant experiences of their lifetime at 16-month follow-up. The sessions also increased engagement in contemplative practices and appreciation of other religious traditions. These were professionally trained religious leaders with decades of prior spiritual experience who still rated the psilocybin sessions as extraordinary.

Is a psilocybin experience the same as a religious experience?

Researchers have documented that psilocybin-occasioned experiences and near-death experiences produce comparably significant changes in death attitudes and sense of meaning (Sweeney et al., 2022), and that professional clergy rate psilocybin sessions among the most spiritually significant events of their trained careers. Whether the experiences are the same in any theological sense remains unresolved — science can measure the phenomenology and its effects but cannot determine whether psilocybin occasions genuine sacred experience or produces its functional equivalent. Participants across studies consistently describe them as among the most significant experiences of their lives.

Does psilocybin permanently change spiritual beliefs?

Long-term follow-up data suggests the changes are durable rather than permanent in a static sense. At 14-month follow-up of the Griffiths 2006 cohort, 67% still rated their psilocybin session as among the most spiritually significant events of their lives. At 4.5-year follow-up of the NYU cancer cohort (Agin-Liebes 2020), 71% still ranked it among their most personally meaningful experiences. MacLean and colleagues (2011) found lasting increases in the personality trait of Openness that persisted at 14 months. These changes appear to be ongoing reorganizations of how people understand themselves, not one-time events.

Sources & References

1. 1RTHM-02089·Griffiths, Roland R et al. (2025). “Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions..” Psychedelic medicine (New Rochelle.Study breakdown →PubMed →↩
2. 2. Source details for this reference are not yet available.
3. 3RTHM-00250·Griffiths, Roland R et al. (2008). “Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later..” Journal of Psychopharmacology.Study breakdown →PubMed →↩
4. 4RTHM-00422·MacLean, Katherine A et al. (2011). “Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness..” Journal of psychopharmacology (Oxford.Study breakdown →PubMed →↩
5. 5RTHM-01623·Sweeney, Mary M et al. (2022). “Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying..” PloS one.Study breakdown →PubMed →↩
6. 6RTHM-01160·Agin-Liebes, Gabrielle I et al. (2020). “Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer..” Journal of psychopharmacology (Oxford.Study breakdown →PubMed →↩